Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiopulmonary Resuscitation III: AED Use

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Novel Oral Anticoagulants (NOACs) Roundtable - Hot Topics and Current Issues in association with <i>Arrhythmia & Electrophysiology Review</i>: Roundtable Event Held on 12 November 2014 in London, UK Reviewed for accuracy by.

Arrhythmia & electrophysiology review·2025

Same author

Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data.

BMJ (Clinical research ed.)·2021

Same author

Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors.

Stroke·2021

Same author

Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry.

Annals of medicine·2021

Same author

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry.

Internal and emergency medicine·2020

Same author

GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke.

Future cardiology·2020

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

[Implantable cardioverter defibrillator: an update].

Jean-Yves le Heuzey¹, Etienne Aliot

¹Cardiologie A, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France. jean-yves.le-heuzey@egp.ap-hop-paris.fr

Medecine Sciences : M/S

|January 11, 2007

Summary

Automatic implantable cardioverter defibrillators (AICDs) are crucial for preventing sudden cardiac death. Guidelines recommend AICDs for secondary prevention and specific primary prevention cases, including heart failure and ventricular arrhythmias, based on robust evidence.

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Related Experiment Videos

Last Updated: Jul 17, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Area of Science:

Cardiology
Electrophysiology
Medical Devices

Context:

Sudden cardiac death (SCD) remains a significant cause of mortality.
Automatic implantable cardioverter defibrillators (AICDs) are established therapies for SCD prevention.
Clinical guidelines provide indications for AICD implantation in various patient populations.

Purpose:

To outline the established and recommended indications for AICD implantation.
To detail the evidence levels supporting these recommendations.
To summarize current guidelines for AICD use in preventing sudden cardiac death.

Summary:

AICDs are indicated for secondary prevention in patients with prior cardiac arrest, barring reversible causes (Level A).
Primary prevention indications include coronary artery disease patients with reduced ejection fraction (≤30%) and heart failure (NYHA II-III) (Level B).
Further indications involve symptomatic ventricular tachycardias, syncope with inducible arrhythmias, and specific cases of cardiomyopathy and heart failure with CRT.

Impact:

Provides clear guidance for clinicians on AICD implantation decisions.
Aims to improve patient outcomes by reducing sudden cardiac death.
Highlights the role of AICDs in managing high-risk cardiovascular conditions.